Fig. 1

Overexpression of XPO1 was correlated to poor prognosis of GBC patients. A The comparison of XPO1 mRNA expression level between GBC tumor tissues and adjacent non-tumor tissues using qRT-PCR (n = 35). B Relative XPO1 expression level in GBC tissues and their corresponding non-tumor tissues (2 − ΔCT) (n = 35). Student's t test was applied to the statistical analysis. C Representative images of GBC IHC staining with an anti-XPO1 antibody. (a, b) Negative expression of XPO1 in cholecystitis tissues; (c, d) weak expression of XPO1 in GBC tissues; (e, f) moderate expression of XPO1 in GBC tissues; (g, h) strong expression of XPO1 in GBC tissues. Scale bars represent 100 μm. D Average staining scores for XPO1 expression in GBC tumor tissues (n = 92) and Cholecystitis tissues (n = 69) (P < 0.001) tested by Student's t test. E Patients with high XPO1 protein expression present shorter overall survival time assessed by Kaplan–Meier test